JPMorgan Positive on Apellis Pharmaceuticals (APLS): 'we believe that pegcetacoplan’s pole position in the disease space has been solidified'
Tweet Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments "On BCVA pushback related to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
